Mablink Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Employees
-
34
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$278M
Mablink General Information
Description
Operator of a biotechnology company intended to develop antibody-drug-conjugates drugs to fight cancer. The company helps to design homogenous, plasma-stable conjugates with a high drug-antibody ratio while retaining original pharmacological properties, enabling healthcare professionals to provide patients with new and improved treatment options for cancer.
Contact Information
Website
www.mablink.comCorporate Office
- 31 Rue Gorge de Loup
- 69009 Lyon
- France
Corporate Office
- 31 Rue Gorge de Loup
- 69009 Lyon
- France
Mablink Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 01-Dec-2023 | $278M | Completed | Generating Revenue | ||
| 6. Early Stage VC (Series A) | 31-Jul-2022 | Completed | Generating Revenue | |||
| 5. Seed Round | 27-Apr-2021 | Completed | Pre-Clinical Trials | |||
| 4. Seed Round | 19-Sep-2019 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | 15-May-2019 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 01-Jan-2019 | Completed | Startup | |||
| 1. Grant | 01-Jan-2019 | $1.71M | Completed | Startup |
Mablink Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Shares A | ||||||||
| S Shares | ||||||||
| Ordinary | 1,850 | $1.019323 | $72.4 | $72.4 | 1x | $72.4 | 1.07% | |
| Ordinary | 1,670 | $1.019323 | $9.17 | $9.17 | 1x | $9.17 | 0.97% |
Mablink Comparisons
Industry
Financing
Details
Mablink Competitors (22)
One of Mablink’s 22 competitors is Oxford Biotherapeutics, a Private Equity-Backed company based in Oxford, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Oxford Biotherapeutics | Private Equity-Backed | Oxford, United Kingdom | ||||
| Byondis | Corporation | Nijmegen, Netherlands | ||||
| Vir Biotechnology | Formerly VC-backed | San Francisco, CA | ||||
| Meditope Biosciences | Formerly VC-backed | Pasadena, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
Mablink Patents
Mablink Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4788379-A1 | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | Pending | 02-Oct-2023 | ||
| US-12419964-B2 | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | Active | 02-Oct-2023 | ||
| US-20250127916-A1 | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | Active | 02-Oct-2023 | ||
| US-20260021194-A1 | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | Pending | 02-Oct-2023 | ||
| WO-2025073812-A1 | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | Inactive | 02-Oct-2023 | A61K47/68037 |
Mablink Signals
Mablink Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angelor | Venture Capital | Minority | ||
| BigBooster | Accelerator/Incubator | |||
| Bpifrance | Sovereign Wealth Fund | Minority | ||
| Crédit Agricole Création | Venture Capital | Minority | ||
| Elaia Partners | Venture Capital | Minority |
Mablink FAQs
-
When was Mablink founded?
Mablink was founded in 2018.
-
Where is Mablink headquartered?
Mablink is headquartered in Lyon, France.
-
What is the size of Mablink?
Mablink has 34 total employees.
-
What industry is Mablink in?
Mablink’s primary industry is Drug Discovery.
-
Is Mablink a private or public company?
Mablink is a Private company.
-
What is the current valuation of Mablink?
The current valuation of Mablink is .
-
What is Mablink’s current revenue?
The current revenue for Mablink is .
-
How much funding has Mablink raised over time?
Mablink has raised $36.4M.
-
Who are Mablink’s investors?
Angelor, BigBooster, Bpifrance, Crédit Agricole Création, and Elaia Partners are 5 of 16 investors who have invested in Mablink.
-
Who are Mablink’s competitors?
Oxford Biotherapeutics, Byondis, Vir Biotechnology, Meditope Biosciences, and CytomX Therapeutics are some of the 22 competitors of Mablink.
-
When was Mablink acquired?
Mablink was acquired on 01-Dec-2023.
-
Who acquired Mablink?
Mablink was acquired by Lilly USA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process